Home › Research › Clinical trials
Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials
Cummings JL, Atri A, Scheltens P, et al.. The Lancet, 2026
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
EVOKE (ClinicalTrials.gov NCT04777396) and EVOKE+ (NCT04777409) tested whether oral semaglutide, the GLP-1 diabetes/weight-loss drug, could slow early Alzheimer's disease progression in a combined 3,808 participants over up to 156 weeks. Neither trial showed a benefit on the main measure of decline (CDR-SB): the difference from placebo was essentially zero in both studies. Semaglutide did modestly lower some brain-inflammation and tau biomarkers in spinal fluid/blood, but this did not translate into any detectable slowing of cognitive or functional decline, and side effects (nausea, appetite loss, weight loss) were more common than with placebo. Novo Nordisk ended its Alzheimer's program for semaglutide after this result.
What this study adds
Evidence grade: Null result
The record lists 3,808 participants. In two Phase 3 trials of 3,808 participants, oral semaglutide showed no significant difference from placebo in clinical decline on the main measure, and Novo Nordisk ended its Alzheimer's program for the drug after this result. Reported effect size: EVOKE difference -0.08 (95% CI -0.35 to 0.20); EVOKE+ difference 0.10 (95% CI -0.17 to 0.38).
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Cummings, J. L., Atri, A., Scheltens, P., et al. (2026). Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials. The Lancet. https://doi.org/10.1016/s0140-6736(26)00459-9
Vancouver
Cummings JL, Atri A, Scheltens P, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials. The Lancet. 2026. doi:10.1016/s0140-6736(26)00459-9. PMID: 41865758.
BibTeX
@article{cummings2026-c800c391,
author = {Cummings, J. L. and Atri, A. and Scheltens, P. and others},
title = {{Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (EVOKE and EVOKE+): two phase 3, randomised, placebo-controlled trials}},
journal = {The Lancet},
year = {2026},
doi = {10.1016/s0140-6736(26)00459-9},
pmid = {41865758},
url = {https://doi.org/10.1016/s0140-6736(26)00459-9}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Combined enrollment 3,808 (EVOKE n=1,855; EVOKE+ n=1,953) across 566 sites/40 countries; Phase 3, randomized, double-blind, placebo-controlled, sponsored by Novo Nordisk
- No significant difference in clinical decline (CDR-SB) between semaglutide and placebo in either trial: EVOKE difference −0.08 (95% CI −0.35 to 0.20, p=0.57); EVOKE+ difference 0.10 (95% CI −0.17 to 0.38, p=0.46)
- Some biomarker reductions (up to ~10% in p-tau181, p-tau217, and inflammation markers) did not translate into clinical benefit
- More treatment-emergent adverse events (largely GI symptoms, weight loss) with semaglutide (91.2%) than placebo (84.8%)
Why it matters
In two Phase 3 trials of 3,808 participants, oral semaglutide showed no significant difference from placebo in clinical decline on the main measure, and Novo Nordisk ended its Alzheimer's program for the drug after this result. Some biomarker reductions did not translate into any detectable slowing of cognitive or functional decline.
New to this subject? Start with our plain-English guide: Registered clinical trials →
Study details
- Study designphase-3-trial
- Participants3,808
- Effect sizeEVOKE difference -0.08 (95% CI -0.35 to 0.20); EVOKE+ difference 0.10 (95% CI -0.17 to 0.38)
- Evidence strengthNull-result
Limitations
Definitively null result on the primary clinical endpoint despite large size; conducted only in already-symptomatic AD, so it doesn't address earlier preventive use; more GI adverse events (91.2% vs. 84.8%) with semaglutide.
How this study scored 81/100
Published in a top-tier journal, and it is a large phase 3 trial. Scored zero for indexed in PubMed because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 50 of the 62 points we could judge it on, which is 81 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 10 / 10 | Tier 1 — top-tier general journal (The Lancet) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A large phase 3 trial |
| Strength of evidence | 3 / 5 | Rated “null-result” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 5 / 5 | 2026 — within 1 year(s) of the newest study here |
| Sample size | 3 / 4 | 3,808 participants |
| Effect reported | 3 / 3 | Effect reported with a statistic (interval, p-value, ratio or similar) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 0 / 2 | No PubMed ID and no DOI — scores zero (not stated in the record — scored 0) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 50 / 62 | Scored on 11 of 20 parts. We have no data for the rest, so they are left out: 50 of the 62 points we could judge it on is 81 out of 100. |
| Total | 81 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
2 studies in the alzhub library list this one in their references.
Related studies in Clinical trials from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.